Day 653: Slapdowns

This week was big on dissing the vaxx: the Fifth Circuit stayed OSHA's overreaching vaccine mandate, in language that forebodes a final slapdown to come:

On the dubious assumption that the Mandate does pass constitutional muster—which we need not decide today—it is nonetheless fatally flawed on its own terms. Indeed, the Mandate's strained prescriptions combine to make it the rare government pronouncement that is both overinclusive (applying to employers and employees in virtually all industries and workplaces in America, with little attempt to account for the obvious differences between the risks facing, say, a security guard on a lonely night shift, and a meatpacker working shoulder to shoulder in a cramped warehouse) and underinclusive (purporting to save employees with 99 or more coworkers from a "grave danger" in the workplace, while making no attempt to shield employees with 98 or fewer coworkers from the very same threat). The Mandate's stated impetus—a purported "emergency" that the entire globe has now endured for nearly two years, and which OSHA itself spent nearly two months responding to threat). The Mandate's stated impetus—a purported "emergency" that the entire globe has now endured for nearly two years, and which OSHA itself spent nearly two months responding to—is unavailing as well. And its promulgation grossly exceeds OSHA's statutory authority.

A smaller slapdown comes from some Swedish doctors and researchers, who have an extremely anti-vaxx response to recent whistle-blowing documented by the British Medical Journal:

The group’s statement in a November 5 press release came in light of a whistleblower’s testimony to the prestigious British Medical Journal (BMJ), alleging that a Pfizer subcontractor company had falsified data, unblinded trial participants, and neglected the timely follow-up of subjects experiencing adverse events as they conducted a Pfizer COVID-19 vaccine trial in the fall of 2020.

Brook Jackson, a “trained clinical trial auditor” with more than “15 years’ experience in clinical research coordination and management,” worked for Ventavia Research Group of Texas for two weeks in September 2020 and was fired the day she raised her concerns to the U.S. Food and Drug Administration (FDA).

It's starting to look like an Ayn Rand novel around here...